[Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy]

Med Sci (Paris). 2007 Mar;23(3):257-8. doi: 10.1051/medsci/2007233257.
[Article in French]
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Antigens, Differentiation
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Calreticulin / biosynthesis
  • Calreticulin / genetics
  • Calreticulin / physiology*
  • Calreticulin / therapeutic use
  • Cell Cycle Proteins / antagonists & inhibitors
  • Cell Death / immunology
  • Dendritic Cells / immunology
  • Gene Expression Regulation / drug effects
  • Immune System / drug effects*
  • Immune System / radiation effects*
  • Interferon-gamma / physiology
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / radiation effects
  • Mice
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / radiotherapy
  • Neoplasms, Experimental / drug therapy
  • Neoplasms, Experimental / immunology
  • Neoplasms, Experimental / radiotherapy
  • Phagocytosis
  • Phosphoprotein Phosphatases / antagonists & inhibitors
  • Protein Phosphatase 1
  • Rats
  • Recombinant Proteins / therapeutic use
  • T-Lymphocyte Subsets / immunology

Substances

  • Antigens, Differentiation
  • Antineoplastic Agents
  • Calreticulin
  • Cell Cycle Proteins
  • Neoplasm Proteins
  • Recombinant Proteins
  • Interferon-gamma
  • PPP1R15A protein, human
  • Phosphoprotein Phosphatases
  • Ppp1r15a protein, mouse
  • Protein Phosphatase 1